Abdur Rauf
Abdur Rauf, PhD, is a distinguished member of the Department of Chemistry at the University of Swabi, KP, Pakistan. Having earned his PhD from the Institute of Chemical Sciences, University of Peshawar, Pakistan in 2015, Dr. Rauf has dedicated his career to advancing the realms of Phytochemistry and Pharmacology. His primary focus lies in the bio-guided isolation of new compounds for drug discovery. Dr. Rauf's research endeavors encompass the isolation and elucidation of bioactive compounds, employing innovative techniques for in vitro and in vivo biological screening. His scholarly contributions are remarkable, evidenced by authoring or coauthoring over 430 research papers in esteemed peer-reviewed journals, boasting an impact factor of 1760.65. Garnering over 14,000 citations according to Google Scholar, Dr. Rauf holds an H-index of 61 and an i10 index of 275. Additionally, he has edited five books and contributed 39 chapters to international publications. Notably, he holds one national and one international patent, with four more international patents pending, all pertaining to the discovery of novel antidiabetic drugs. Dr. Rauf's influence extends beyond academia, as he serves as an Associate Editor or Editorial Board member for prestigious journals such as "Frontier in Pharmacology," "Heliyon," "Biocell," "Green Processing and Synthesis," and "Medicinal Chemistry." He is also a fellow of the American Chemical Society and "Bioconlab" at Oral State University, Russia. Acknowledged as one of the World's Top 1% Highly Cited Researchers in 2022 by Clarivate, Dr. Rauf's impact is undeniable. Throughout his career, Dr. Rauf has demonstrated a commitment to nurturing future talent, having supervised three PhD and ten MPhil students. His accolades include the Young Scientist Award from the Directorate of Science and Technology KP, Pakistan in 2018, and the Research Productivity Award for 2016-17 from the Pakistan Science Foundation. Noteworthy among his achievements is the organization of the "1st International Conference on Drug Discovery against Cancer and other Diseases (DDCD)" in 2019, along with participation in the "International Pharmacy Conference & Exhibition on Emerging Trends in Drug Development, Therapeutics, and Commercialization (2019)." Driven by a vision for sustainable innovation, Dr. Rauf's future research aims to develop eco-friendly and cost-effective protocols for producing nanoparticle-based drugs with biomedical applications. He also seeks to harness local natural resources, particularly the national flora, to address various health disorders, thereby contributing significantly to the national economy.